Cequent Begins Long-Term Tox Study with FAP Drug

The company said the toxicology work, which is being conducted in non-human primates, will lay the groundwork for a phase II study to begin in 2011.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.